A large proportion of women present with advanced breast cancer in the developing countries with limitedresources. Many of these patients have ulcerated, bleeding lesions or visually obvious masses in the breast.Neoadjuvant chemotherapy is well established as the standard of care and initial management of choice forthese patients. Tumor shrinkage achieved with neoadjuvant chemotherapy has the advantage of converting aninoperable disease to an operable condition, with the option of breast conservation surgery where mastectomyis the only initial option for loco-regional control. Neoadjuvant chemotherapy also provides the earliest possibletreatment of micrometastases and thus improves survival. In the present study, 165 advanced breast cancerfemale patients registered at the Institute of Nuclear Medicine and Oncology, Lahore, Pakistan, between 1st July2005 and 30th June 2007 were evaluated for response to neoadjuvant chemotherapy. Tumor measurements weremade and recorded prior to the first cycle of chemotherapy and 3 weeks after the third cycle. A clinical completeresponse was seen in 7.3%, a partial response in 60%, stable disease in 24% and progressive disease in 9%. Acomplete pathological response was only seen in 3.6% of evaluable patients. We conclude that breast cancer inpatients presenting for neoadjuvant chemotherapy at our facility is more aggressive, generally presents as moreadvanced and bulky local disease, affects a younger population and features a low and unpredictable responseto neoadjuvant chemotherapy.